ACADIA Pharmaceuticals/ACAD

$14.85

1.57%
-
1D1W1MYTD1YMAX

About ACADIA Pharmaceuticals

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Ticker

ACAD

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Stephen Davis

Employees

610

Headquarters

San diego, United States
Website
acadia.com

ACAD Metrics

BasicAdvanced
$2.5B
Market cap
-
P/E ratio
-$0.01
EPS
0.40
Beta
-
Dividend rate
$2.5B
0.39751
$33.99
$14.65
1.9M
2.043
1.855
227.419
-0.23%
-0.41%
-0.36%
3.064
5.364
7.046
39.162
56.43%
98.57%
18.03%

What the Analysts think about ACAD

Analyst Ratings

Majority rating from 20 analysts.
Buy

Price Targets

Average projection from 18 analysts.
83.7% upside
High $39.00
Low $13.00
$14.85
Current price
$27.28
Average price target

ACAD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
8.01% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$206M
-10.91%
Net income
$17M
-63.89%
Profit margin
8.01%
-59.5%

ACAD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 113.68%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$0.01
-$0.40
$0.28
$0.10
-
Expected
-$0.08
-$0.43
$0.30
$0.05
$0.19
Surprise
-112.1%
-6.13%
-7.85%
113.68%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for ACADIA Pharmaceuticals stock?

ACADIA Pharmaceuticals (ACAD) has a market cap of $2.5B as of May 30, 2024.

What is the P/E ratio for ACADIA Pharmaceuticals stock?

The price to earnings (P/E) ratio for ACADIA Pharmaceuticals (ACAD) stock is 0 as of May 30, 2024.

Does ACADIA Pharmaceuticals stock pay dividends?

No, ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next ACADIA Pharmaceuticals dividend payment date?

ACADIA Pharmaceuticals (ACAD) stock does not pay dividends to its shareholders.

What is the beta indicator for ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals (ACAD) has a beta rating of 0.4. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the ACADIA Pharmaceuticals stock price target?

The target price for ACADIA Pharmaceuticals (ACAD) stock is $27.28, which is 83.7% above the current price of $14.85. This is an average based on projections from 18 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell ACADIA Pharmaceuticals stock

Buy or sell ACADIA Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing